VIB is organising its 5th Biotechday. All ages are welcome to this free event at campus Gasthuisberg in Leuven. reMYND will be presenting on the research towards the treatment of Alheimers and diabetes worldwide.
reMYND’s Tau.P301L and Tau.P301S models feature progressive hyperphosphorylation of Tau with age and a strong correlation of Tau pathology with the motor phenotype.
reMYND NV today announced that it has received a grant from IWT, the Flemish agency for Innovation by Science and Technology, to assess the potential of its Diabetes program in curing Type 1 Diabetes Mellitus (T1DM).
Two-photon imaging allows tracking the formation of Tau aggregates in the same brain-region of a live animal over the course of time. This makes it possible to study the effects of treatment longitudinally in vivo.